Vascular endothelial protein tyrosine phosphatase (VE-PTP) is an endothelial-specific receptor-type tyrosine phosphatase that associates with Tie-2 and VE-cadherin. VE-PTP gene disruption leads to embryonic lethality, vascular remodeling defects, and enlargement of vascular structures in extraembryonic tissues. We show here that antibodies against the extracellular part of VE-PTP mimic the effects of VE-PTP gene disruption exemplified by vessel enlargement in allantois explants. These effects require the presence of the angiopoietin receptor Tie-2. Analyzing the mechanism we found that anti-VE-PTP antibodies trigger endocytosis and selectively affect Tie-2-associated, but not VE-cadherin-associated VE-PTP. Dissociation of VE-PTP triggers the activation of Tie-2, leading to enhanced endothelial cell proliferation and enlargement of vascular structures through activation of Erk1/2. Importantly, the antibody effect on vessel enlargement is also observed in newborn mice. We conclude that VE-PTP is required to balance Tie-2 activity and endothelial cell proliferation, thereby controlling blood vessel development and vessel size.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2711575PMC
http://dx.doi.org/10.1083/jcb.200811159DOI Listing

Publication Analysis

Top Keywords

ve-ptp
8
blood vessel
8
vessel development
8
tie-2 activity
8
tyrosine phosphatase
8
ve-ptp gene
8
gene disruption
8
enlargement vascular
8
vascular structures
8
vessel enlargement
8

Similar Publications

Despite its importance in pathogenesis, the hematogenous dissemination pathway of is still largely uncharacterized. To probe the molecular details of transendothelial migration more easily, we studied this process using cultured primary or telomerase-immortalized human microvascular endothelial cells in a medium that maintains both the human cells and the spirochetes. In -infected monolayers, we observed ~55% of wild-type spirochetes crossing the monolayer.

View Article and Find Full Text PDF

Deficient Angiopoietin-Tie2 signaling is linked to ocular hypertension in glaucoma. Receptor Tie2/TEK expression and signaling at Schlemm's canal (SC) is indispensable for canal integrity and homeostatic regulation of aqueous humor outflow (AHO) and intraocular pressure (IOP), as validated by conditional deletion of Tie2, its ligands (Angpt1, Angpt2 and Angpt3/4) or regulators (Tie1 and PTPRB/VE-PTP). However, these Tie2/TEK knockouts and conditional knockouts are global or endothelial, preventing separation of systemic and ocular vascular defects that impact retinal or renal integrity.

View Article and Find Full Text PDF

Unlabelled: Despite its importance in pathogenesis, the hematogenous dissemination pathway of is still largely uncharacterized. To probe the molecular details of transendothelial migration more easily, we studied this process using cultured primary or telomerase-immortalized human microvascular endothelial cells in a medium that maintains both the human cells and the spirochetes. In infected monolayers we observed ∼55% of wild-type spirochetes crossing the monolayer.

View Article and Find Full Text PDF

Aims: SCUBE2 (signal peptide-CUB-epidermal growth factor-like domain-containing protein 2) is a secreted or membrane-bound protein originally identified from endothelial cells (ECs). Our previous work showed that SCUBE2 forms a complex with E-cadherin and stabilizes epithelial adherens junctions (AJs) to promote epithelial phenotypes. However, it remains unclear whether SCUBE2 also interacts with vascular endothelial (VE)-cadherin and modulates EC barrier function.

View Article and Find Full Text PDF

Beyond VEGF: Angiopoietin-Tie Signaling Pathway in Diabetic Retinopathy.

J Clin Med

May 2024

Asociados de Mácula Vitreo y Retina de Costa Rica, San José 60612, Costa Rica.

Article Synopsis
  • Diabetic retinopathy, especially complications like diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR), significantly contribute to preventable vision loss in working-age individuals, largely due to the role of vascular endothelial growth factor (VEGF) in their development.
  • Current treatments primarily involve anti-VEGF therapies, but many patients are undertreated, leading to poor outcomes and a high prevalence of persistent DME despite treatment.
  • The new bi-specific antibody, faricimab, shows promise for better long-term results by targeting both the Angiopoietin-Tie and VEGF pathways, as demonstrated in the YOSEMITE and RHINE clinical trials, which revealed comparable vision improvements and potential
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!